Skip to main content
    V

    Viking Therapeutics Inc (VKTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $26.80
    -2.42 (-8.28%)

    Market Cap: $3.73B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Viking Therapeutics Inc (VKTX) Earnings: Report Dates and Results

    Updated Oct 28, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Viking Therapeutics (VKTX) is expected to report earnings on Feb 9, 2027. In the quarter ended Sep 30, 2026, Viking Therapeutics reported EPS of -$1.55, below the -$1.06 estimate. It beat the EPS estimate in 1 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    43%(17/40)
    Avg Surprise
    -2.63%

    Upcoming Estimates

    Reports Feb 9, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$1.32
    Range-$1.60 - -$0.79
    22 analysts
    Revenue Consensus
    N/A
    RangeN/A
    19 analysts
    Reports Apr 27, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$1.36
    Range-$1.71 - -$1.12
    7 analysts
    EPS Revisions
    1
    3
    30d
    EPS Estimate DriftChange to current
    90d ago-$1.05-29.4%
    60d ago-$1.05-29.4%
    30d ago-$1.05-29.4%
    7d ago-$1.04-30.4%
    Current-$1.36
    Revenue Consensus
    N/A
    RangeN/A
    7 analysts

    Next Report

    VKTX has an expected report date of Feb 9, 2027.

    VKTX Earnings Call

    The latest VKTX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, VKTX beat 17, missed 19 and matched 4. The widest gap in the table came in the quarter ended Dec 31, 2025, when EPS landed 53.33% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$1.55-$1.06-$1.38 - -$0.66-46.23%MissN/A179 up, 6 downOct 28, 2026
    Jun 30, 2026-$1.10-$1.21-$1.39 - -$0.83+9.09%BeatN/A163 up, 8 downJul 29, 2026
    Mar 31, 2026-$1.37-$0.91-$1.43 - -$0.58-50.55%MissN/A12N/AApr 29, 2026
    Dec 31, 2025-$1.38-$0.90-$1.06 - -$0.79-53.33%MissN/A140 up, 1 downFeb 11, 2026
    Sep 30, 2025-$0.81-$0.67-$0.80 - -$0.44-20.90%MissN/A120 up, 0 downOct 22, 2025
    Jun 30, 2025-$0.58-$0.44-$0.55 - -$0.37-31.82%MissN/A160 up, 10 downJul 23, 2025
    Mar 31, 2025-$0.41-$0.31-$0.42 - -$0.16-32.26%MissN/A120 up, 3 downApr 23, 2025
    Dec 31, 2024-$0.32-$0.27-$0.34 - -$0.22-18.52%MissN/A123 up, 3 downFeb 5, 2025
    Sep 30, 2024-$0.22-$0.24-$0.32 - -$0.21+8.33%BeatN/A130 up, 0 downOct 23, 2024
    Jun 30, 2024-$0.20-$0.27-$0.32 - -$0.17+25.93%BeatN/A120 up, 0 downJul 24, 2024
    Mar 31, 2024-$0.26-$0.28-$0.32 - -$0.24+7.14%BeatN/A100 up, 0 downApr 24, 2024
    Dec 31, 2023-$0.25-$0.25-$0.28 - -$0.220.00%In lineN/A91 up, 0 downFeb 7, 2024
    Sep 30, 2023-$0.23-$0.22-$0.24 - -$0.18-4.55%MissN/A111 up, 0 downOct 25, 2023
    Jun 30, 2023-$0.19-$0.20-$0.24 - -$0.15+5.00%BeatN/A110 up, 0 downJul 26, 2023
    Mar 31, 2023-$0.25-$0.24-$0.27 - -$0.21-4.17%MissN/A100 up, 0 downApr 26, 2023
    Dec 31, 2022-$0.26-$0.23-$0.28 - -$0.21-13.04%MissN/A100 up, 0 downFeb 8, 2023
    Sep 30, 2022-$0.21-$0.23-$0.25 - -$0.20+8.70%BeatN/A101 up, 0 downOct 26, 2022
    Jun 30, 2022-$0.23-$0.21-$0.24 - -$0.18-9.52%MissN/A101 up, 0 downJul 27, 2022
    Mar 31, 2022-$0.21-$0.19-$0.23 - -$0.18-10.53%MissN/A90 up, 0 downApr 27, 2022
    Dec 31, 2021-$0.16-$0.19-$0.22 - -$0.17+15.79%BeatN/A90 up, 0 downFeb 9, 2022
    Sep 30, 2021-$0.17-$0.21-$0.23 - -$0.20+19.05%BeatN/A10N/ANov 3, 2021
    Jun 30, 2021-$0.20-$0.20-$0.21 - -$0.190.00%In lineN/A13N/AJul 28, 2021
    Mar 31, 2021-$0.19-$0.17-$0.20 - -$0.15-11.76%MissN/A14N/AApr 28, 2021
    Dec 31, 2020-$0.15-$0.15-$0.18 - -$0.120.00%In lineN/A15N/AFeb 17, 2021
    Sep 30, 2020-$0.13-$0.15-$0.20 - -$0.13+13.33%BeatN/A15N/AOct 28, 2020
    Jun 30, 2020-$0.13-$0.14-$0.17 - -$0.12+7.14%BeatN/A15N/AJul 29, 2020
    Mar 31, 2020-$0.13-$0.12-$0.14 - -$0.10-8.33%MissN/A11N/AApr 30, 2020
    Dec 31, 2019-$0.10-$0.13-$0.16 - -$0.09+23.08%BeatN/A12N/AFeb 26, 2020
    Sep 30, 2019-$0.08-$0.12-$0.17 - -$0.11+33.33%BeatN/A12N/ANov 5, 2019
    Jun 30, 2019-$0.11-$0.09-$0.12 - -$0.07-22.22%MissN/A11N/AAug 1, 2019
    Mar 31, 2019-$0.07-$0.09-$0.10 - -$0.06+22.22%BeatN/A9N/AMay 2, 2019
    Dec 31, 2018-$0.07-$0.10-$0.12 - -$0.09+30.00%BeatN/A10N/AMar 13, 2019
    Sep 30, 2018-$0.11-$0.11-$0.14 - -$0.100.00%In lineN/A7N/ANov 7, 2018
    Jun 30, 2018-$0.13-$0.12-$0.14 - -$0.08-8.33%MissN/A6N/AAug 9, 2018
    Mar 31, 2018-$0.08-$0.12-$0.17 - -$0.09+33.33%BeatN/A4N/AMay 9, 2018
    Dec 31, 2017-$0.14-$0.17-$0.20 - -$0.12+17.65%BeatN/A4N/AMar 7, 2018
    Sep 30, 2017-$0.22-$0.20N/A-10.00%MissN/AN/AN/ANov 8, 2017
    Jun 30, 2017-$0.21-$0.19N/A-10.53%MissN/AN/AN/AAug 9, 2017
    Mar 31, 2017-$0.23-$0.18N/A-27.78%MissN/AN/AN/AMay 10, 2017
    Dec 31, 2016-$0.18-$0.20N/A+10.00%BeatN/AN/AN/AMar 21, 2017
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.18, after -$1.00 the year before. It was -$1.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.18N/A
    Dec 31, 2024-$1.00N/A
    Dec 31, 2023-$0.92N/A
    Dec 31, 2022-$0.91N/A
    Dec 31, 2021-$0.72N/A
    Dec 31, 2020-$0.54N/A
    Dec 31, 2019-$0.36N/A
    Dec 31, 2018-$0.39N/A
    Dec 31, 2017-$0.80N/A
    Dec 31, 2016-$1.00N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,700 words across 22 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,67122
    2026Q2Jun 30, 20267,47219
    2025Q4Dec 31, 20256,24417
    2025Q3Sep 30, 20256,46717
    2025Q2Jun 30, 20255,55918
    2024Q4Dec 31, 20246,15116
    2024Q3Sep 30, 20246,68614
    2024Q2Jun 30, 20246,91414

    2026Q3 Earnings Call

    Opening remarks

    Stephanie Diaz Manager of Investor Relations Hello, and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; Greg Zante, Viking's CFO; and Hubert Chen, Viking's Chief Medical Officer. Before we begin, I'd like to caution that comments made during this conference call today, October 28, 2026, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, timelines and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters. I'll now turn the call over to Brian Lian for his initial comments.

    Brian Lian President and CEO Thanks, Stephanie, and good afternoon to everyone listening in by phone or on the webcast. Today, we'll review our financial results for the third quarter and 9 months ended September 30, 2026, and review recent updates across our pipeline programs and organization. During the third quarter, we made important progress across multiple pipeline programs and announced positive results from an innovative maintenance dosing study in our obesity program. With respect to our lead compound, VK2735, a dual agonist of the GLP-1 and GIP receptors, Viking's Phase III VANQUISH clinical program continued to proceed according to plan. The VANQUISH program is evaluating the subcutaneous formulation of VK2735 in two studies: VANQUISH-1 in adults with obesity and VANQUISH-2 in adults with obesity and type 2 diabetes. Both trials are fully enrolled, and during the third quarter, both continued to advance toward completion. In addition, during the third quarter, the company made significant progress with its oral VK2735 program. Earlier this month, we announced the initiation of the SUNRISE Phase III registration program. As with the VANQUISH program for subcutaneous VK2735, the SUNRISE Phase III program consists of two studies, one evaluating the treatment of adults with obesity and the other evaluating adults with obesity and type 2 diabetes. We're very happy to have these important studies underway, and I'll provide more details on them in a few minutes. During the quarter, we also announced positive data from our novel VK2735 maintenance dosing study. Part 1 of this study was focused on our subcutaneous formulation and demonstrated an exciting signal that indicates the potential for novel dosing strategies to manage weight loss long term with lower and less frequent dosing regimens.

    Frequently Asked Questions About VKTX

    When is Viking Therapeutics's next earnings date?

    Viking Therapeutics's next earnings report is expected for Feb 9, 2027.

    Did VKTX beat earnings estimates last quarter?

    No. Viking Therapeutics reported EPS of -$1.55 for the quarter ended Sep 30, 2026, below the -$1.06 estimate by 46.23%.

    What EPS do analysts expect from VKTX next quarter?

    The consensus EPS estimate for Viking Therapeutics for the quarter ending Dec 31, 2026 is -$1.32 from 22 analysts, with estimates from -$1.60 to -$0.79.

    How often does VKTX beat earnings estimates?

    Viking Therapeutics beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -30.56%.